NYSE - Nasdaq Real Time Price USD

Bausch Health Companies Inc. (BHC)

Compare

7.88

+0.05

+(0.64%)

At close: January 10 at 4:00:01 PM EST

7.77

-0.11

(-1.40%)

After hours: January 10 at 7:24:12 PM EST

Is Bausch + Lomb (BLCO) the Best Medical Stock to Buy Under $20?

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Bausch + Lomb Corporation (NYSE:BLCO) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ensuring the health and safety of populations. […]

Insider Monkey 17 minutes ago

BHC
+0.64%
BLCO
-1.77%
Is Bausch Health Companies (BHC) the Best Medical Stock to Buy Under $20?

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Bausch Health Companies Inc. (NYSE:BHC) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ensuring the health and safety of populations. […]

Insider Monkey 24 minutes ago

BHC
+0.64%
Here's Why Bausch Health (BHC) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 2 days ago

BHC
+0.64%
Is Bausch Health Companies (BHC) Among Billionaire Paul Singer’s Top Long-Term Stock Picks?

We recently published a list of Billionaire Paul Singer’s Top 12 Long-Term Stock Picks. In this article, we are going to take a look at where Bausch Health Companies Inc. (NYSE:BHC) stands against other Billionaire Paul Singer’s long-term stock picks. The world’s “most feared investor,” Paul Singer, needs no introduction. He has built a reputation […]

Insider Monkey 24 days ago

BHC
+0.64%
Contact lens maker Bausch + Lomb says it is exploring sale

Bausch + Lomb also said its statement was in response to a request from the Canadian Investment Regulatory Organization (CIRO) after a series of media reports on its likely sale triggered volatility in its shares. A month prior, the FT had reported that the company had hired an investment bank to explore a sale, sending its shares surging more than 37% until the newspaper's report on Blackstone's cooling interest earlier this week led to a sharp fall in its stock price. A sale could end a long process by parent Bausch Health to offload its stake in the eyecare company.

Reuters 30 days ago

BHC
+0.64%
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response ...

ACCESSWIRE last month

BHC
+0.64%
Eye health company Bausch + Lomb’s affiliate acquires Elios Vision

The acquisition strengthens Bausch + Lomb's existing portfolio of surgical and pharmaceutical glaucoma treatments.

Medical Device Network last month

BHC
+0.64%
TSX Closer: The Market Surges as the Bank of Canada Makes Its Jumbo Cut, Further Cuts Predicted

Canada's largest stock market, the Toronto Stock Exchange closed higher on Wednesday, climbing after

PREMIUM
MT Newswires last month

BHC
+0.64%
TSX up 105 Points at Midday, With Info Tech, Energy, Higher; Healthcare The Biggest Decliner

The Toronto Stock Exchange is up 105 points with info tech (+1.2%) and energy (+0.6%), the sole gain

PREMIUM
MT Newswires last month

BHC
+0.64%
Bausch + Lomb down after report that Blackstone could back away from takeover bid

Investing.com --Bausch + Lomb Corp (NYSE:BLCO) shares tumbled more than 12% on Wednesday in New York Stock Exchange after report that Blackstone (NYSE:BX) could back away from a joint bid to acquire the eyecare company, raising doubts about one of the largest healthcare buyouts of the year.

Investing.com last month

BHC
+0.64%
BX
Market Chatter: Blackstone Withdraws From Bausch + Lomb Takeover Talks

Blackstone (BX) has decided not to proceed with a joint takeover bid for eyecare company Bausch + Lo

PREMIUM
MT Newswires last month

BHC
+0.64%
BX
Why Is Bausch Health Companies Inc. (BHC) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are going to take a look at where Bausch Health Companies Inc. (NYSE:BHC) stands against the other cosmetic surgery and aesthetics stocks. In the face of economic uncertainty, consumer preferences in the beauty industry […]

Insider Monkey last month

BHC
+0.64%
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day

LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal ...

ACCESSWIRE last month

BHC
+0.64%
Bausch Health Appoints New Chief Medical Officer and Head of R&D

LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition ...

ACCESSWIRE last month

BHC
+0.64%
Why Bausch Health Companies (BHC) is One of the Best Canadian Stocks to Buy Under $10?

We recently published a list of the 10 Best Canadian Stocks to Buy Under $10. In this article, we are going to take a look at why Bausch Health Companies Inc. (NYSE:BHC) is one of the best Canadian stocks to buy under $10. How are Canadian Stocks Performing? The Canadian stock market had a positive […]

Insider Monkey last month

BHC
+0.64%
Why Is Bausch (BHC) Down 11.7% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

BHC
+0.64%
Bausch Health Companies Inc. (NYSE:BHC) is favoured by institutional owners who hold 56% of the company

Key Insights Institutions' substantial holdings in Bausch Health Companies implies that they have significant influence...

Simply Wall St. last month

BHC
+0.64%
Bausch (BHC) Upgraded to Buy: Here's What You Should Know

Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks last month

BHC
+0.64%
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug

The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan. The justices declined to hear an appeal by Norwich Pharmaceuticals of a lower court's ruling that its proposed generic would infringe patents owned by Bausch unit Salix Pharmaceuticals for using Xifaxan to treat the liver-related brain disorder hepatic encephalopathy.

Reuters last month

BHC
+0.64%
PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS

LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% ...

ACCESSWIRE last month

BHC
+0.64%

Performance Overview

Return	BHC	S&P/TSX Composite index
YTD	+1.94%	+0.60%
1-Year	-5.17%	+18.10%
3-Year	-70.84%	+17.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bausch Health Companies Inc. (BHC)

Is Bausch + Lomb (BLCO) the Best Medical Stock to Buy Under $20?

Is Bausch Health Companies (BHC) the Best Medical Stock to Buy Under $20?

Here's Why Bausch Health (BHC) is a Strong Momentum Stock

Is Bausch Health Companies (BHC) Among Billionaire Paul Singer’s Top Long-Term Stock Picks?

Contact lens maker Bausch + Lomb says it is exploring sale

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

Eye health company Bausch + Lomb’s affiliate acquires Elios Vision

TSX Closer: The Market Surges as the Bank of Canada Makes Its Jumbo Cut, Further Cuts Predicted

TSX up 105 Points at Midday, With Info Tech, Energy, Higher; Healthcare The Biggest Decliner

Bausch + Lomb down after report that Blackstone could back away from takeover bid

Market Chatter: Blackstone Withdraws From Bausch + Lomb Takeover Talks

Why Is Bausch Health Companies Inc. (BHC) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?

Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day

Bausch Health Appoints New Chief Medical Officer and Head of R&D

Why Bausch Health Companies (BHC) is One of the Best Canadian Stocks to Buy Under $10?

Why Is Bausch (BHC) Down 11.7% Since Last Earnings Report?

Bausch Health Companies Inc. (NYSE:BHC) is favoured by institutional owners who hold 56% of the company

Bausch (BHC) Upgraded to Buy: Here's What You Should Know

US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug

PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS

Performance Overview